<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04298853</url>
  </required_header>
  <id_info>
    <org_study_id>1910620136</org_study_id>
    <nct_id>NCT04298853</nct_id>
  </id_info>
  <brief_title>Optimal Morphine Dosing Schedule for Neonatal Abstinence Syndrome</brief_title>
  <official_title>Optimal Morphine Dosing Schedule for Neonatal Abstinence Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized pilot trial comparing scheduled morphine dosing with a weaning protocol to
      intermittent morphine dosing on an as-needed basis for newborns with neonatal abstinence
      syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 9, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean</measure>
    <time_frame>8 weeks</time_frame>
    <description>Mean length of hospital stay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Standard deviations</measure>
    <time_frame>8 weeks</time_frame>
    <description>Length of hospital stay</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Neonatal Abstinence Syndrome</condition>
  <condition>Neonatal Opioid Withdrawal</condition>
  <condition>Neonatal Opioid Withdrawal Syndrome</condition>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infants randomized to the standard arm will receive morphine based on the current institutional treatment protocol: oral morphine 0.05 mg/kg/dose given every 3 hours, initiated if threshold Finnegan score is met. Once stabilized, dose will be weaned by 10% of peak dose per day until discontinuation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infants randomized to the study arm will receive oral morphine 0.05 mg/kg/dose as needed for an elevated Finnegan score. May receive morphine as frequently as every 3 hours if needed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine PRN</intervention_name>
    <description>Dose given every 3 hours as-needed for severe NAS, defined by a threshold Finnegan score.</description>
    <arm_group_label>Study</arm_group_label>
    <other_name>morphine</other_name>
    <other_name>morphine sulfate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine scheduled</intervention_name>
    <description>Dose given every 3 hours on a scheduled basis and slowly weaned once stabilized.</description>
    <arm_group_label>Standard</arm_group_label>
    <other_name>morphine</other_name>
    <other_name>morphine sulfate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  newborn greater than or equal to 35 weeks gestation

          -  intrauterine opioid exposure

          -  signs and symptoms of opioid withdrawal

        Exclusion Criteria:

          -  congenital anomalies or suspected genetic condition

          -  co-morbid conditions that require sedation or analgesia due to clinical condition

          -  ongoing need for respiratory support
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>28 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anna Thomas, MD</last_name>
    <phone>317-944-9392</phone>
    <email>aeschwar@iu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leah Engelstad, RN</last_name>
    <phone>317-274-7022</phone>
    <email>leovermy@iu.edu</email>
  </overall_contact_backup>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 4, 2020</study_first_submitted>
  <study_first_submitted_qc>March 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2020</study_first_posted>
  <last_update_submitted>March 5, 2020</last_update_submitted>
  <last_update_submitted_qc>March 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Anna Thomas</investigator_full_name>
    <investigator_title>Assistant Professor of Clinical Pediatrics</investigator_title>
  </responsible_party>
  <keyword>morphine</keyword>
  <keyword>Finnegan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neonatal Abstinence Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Substance Withdrawal Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

